Improvements in Kidney Outcomes Over the Years: Reason for Optimism but a Challenge for Trialists.
Journal article
Zhu D. et al, (2024), Am J Kidney Dis
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
Journal article
EMPA-KIDNEY Collaborative Group None., (2024), Lancet Diabetes Endocrinol, 12, 39 - 50
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
Journal article
EMPA-KIDNEY Collaborative Group None., (2024), The lancet. Diabetes & endocrinology, 12, 51 - 60
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None., (2023), Lancet Diabetes Endocrinol, 11, 905 - 914
Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease
Journal article
Mayne K. et al, (2023), Journal of the American Society of Nephrology
A versatile approach to high-density microcrystals in lipidic cubic phase for room-temperature serial crystallography.
Journal article
Birch J. et al, (2023), J Appl Crystallogr, 56, 1361 - 1370
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group. Electronic address: recoverytrial@ndph.ox.ac.uk None. and RECOVERY Collaborative Group None., (2023), Lancet, 401, 1499 - 1507
Sacubitril/valsartan in Peritoneal Dialysis – Lessons from a Pharmacokinetic Study
Report
Judge P., (2023)
Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors.
Journal article
Chapman D. et al, (2023), Kidney Int
EFFECTS OF EMPAGLIFLOZIN ON KIDNEY AND CARDIACMRI MEASURES IN PATIENTS WITH CHRONIC KIDNEY DISEASE
Conference paper
Judge P., (2023), NEPHROLOGY DIALYSIS TRANSPLANTATION, 38, I48 - I49
Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology.
Journal article
Staplin N. et al, (2022), Hypertension, 79, 2671 - 2681
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
Journal article
Nuffield Department of Population Health Renal Studies Group None. and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium None., (2022), Lancet, 400, 1788 - 1801
Empagliflozin in Patients with Chronic Kidney Disease.
Journal article
EMPA-KIDNEY Collaborative Group None. et al, (2022), N Engl J Med
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
Journal article
RECOVERY Collaborative Group None., (2022), Lancet, 400, 359 - 368
Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial.
Journal article
EMPA-KIDNEY Collaborative Group None., (2022), Nephrol Dial Transplant, 37, 1317 - 1329
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None., (2022), Lancet, 399, 665 - 676
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None., (2022), Lancet, 399, 143 - 151
Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy.
Journal article
Halliday A. et al, (2021), Lancet, 398, 1065 - 1073
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
Working paper
RECOVERY Collaborative Group None., (2021), Lancet, 397, 2049 - 2059